Natriuretic peptide testing for heart failure therapy guidance in the inpatient and outpatient setting

American Journal of Therapeutics

Volumn 16, Issue 2, 2009, Pages 171-177

  Green, Sandy M ^a   Green, Jamie A ^a   Januzzi Jr , James L ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Acutely destabilized heart; B type natriuretic peptide; Cardiac biomarkers; Hospital readmission rates; Mortality; N terminal fragment; NT proBNP

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT; NESIRITIDE; THIAZIDE DIURETIC AGENT;

AMINO TERMINAL SEQUENCE; EMERGENCY WARD; HEART FAILURE; HOSPITAL PATIENT; HUMAN; MORTALITY; OUTPATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; HEART FAILURE; HUMANS; NATRIURETIC PEPTIDE, BRAIN; NATRIURETIC PEPTIDES; PATIENT READMISSION; PEPTIDE FRAGMENTS; PROGNOSIS;

EID: 64549106143     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e318172797f     Document Type: Review

References (39)

1. Kasper EK, Gerstenblith G, Hefter G, et al. A randomized trial of the efficacy of multidisciplinary care in heart failure outpatients at high risk of hospital readmission. J Am Coll Cardiol. 2002;39:471-80.
2. Kay D, Blue A, Pye P, et al. Heart failure: improving the continuum of care. Care Manag J. 2006;7:58-63.
3. Simons WR, Haim M, Rizzo J, et al. Effect of improved disease management strategies on hospital length of stay in the treatment of congestive heart failure. Clin Ther. 1996;18:726-746, discussion 702.
4. Nieminen MS, Bohm M, Cowie MR, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26:384-16.
5. Heart Failure Society of America. Evaluation and management of patients with acute decompensated heart failure. J Card Fail. 2006;12:e86-el03.
6. Al-Meslmani BM, Fahoum SK, Shamia MG. NT-proBNP in monitoring treatment of patients with congestive heart failure. Clin Lab. 2007;53:35-39.
7. Bayes-Genis A, Pascual-Figal D, Fabregat J, et al. Serial NT-proBNP monitoring and outcomes in outpatients with decompensation of heart failure. Int J Cardiol. 2007; 120:338-343.
8. Bayes-Genis A, Santalo-Bel M, Zapico-Muniz E, et al. N-terminal probrain natriuretic peptide (NT-proBNP) in the emergency diagnosis and in-hospital monitoring of patients with dyspnoea and ventricular dysfunction. Eur J Heart Fail. 2004;6:301-308.
9. Cioffi G, Tarantini L, Stefenelli C, et al. Changes in plasma N-terminal proBNP levels and ventricular filling pressures during intensive unloading therapy in elderly with decompensated congestive heart failure and preserved left ventricular systolic function. J Card Fail. 2006;12: 608-615.
10. Januzzi JL, van Kirnmenade R, Lainchbury J, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J. 2006;27: 330-337.
11. CDonoghue M, Chen A, Baggish AL, et al. The effects of ejection fraction on N-terminal ProBNP and BNP levels in patients with acute CHF: analysis from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. J Card Fail. 2005;ll(Suppl 5):S9-S14.
12. Tschope C, Kasner M, Westermann D, et al. The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements. Eur Heart J. 2005;26:2277-2284.
13. Chen AA, Wood MJ, Krauser DG, et al. NT-proBNP levels, echocardiographic findings, and outcomes in breathless patients: results from the ProBNP Investigation of Dyspnoea in the Emergency Department (PRIDE) echocardiographic substudy. Eur Heart J. 2006;27:839-845.
14. Weber M, Arnold R, Rau M, et al. Relation of N-terminal pro-B-type natriuretic peptide to severity of valvular aortic stenosis. Am f Cardiol. 2004;94:740-745.
15. Weber M, Arnold R, Rau M, et al. Relation of N-terminal pro B-type natriuretic peptide to progression of aortic valve disease. Eur Heart J. 2005;26:1023-1030.
16. Morello A, Lloyd-Jones DM, Chae CU, et al. Association of atrial fibrillation and ammo-terminal pro-brain natriuretic peptide concentrations in dyspneic subjects with and without acute heart failure: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. Am Heart J. 2007;153:90-97.
17. Foote RS, Pearlman JD, Siegel AH, et al. Detection of exercise-induced ischemia by changes in B-type natriuretic peptides. J Am Coll Cardiol. 2004;44:1980-1987.
18. Schou M, Gustafsson F, Kjaer A, et al. Long-term clinical variation of NT-proBNP in stable chronic heart failure patients. Eur Heart J. 2007;28:177-182.
19. Wu AH. Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results. Am Heart J. 2006;152:828-834.
20. Bettencourt P, Azevedo A, Pimenta J, et al. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation. 2004;110: 2168-2174.
21. Gegenhuber A, Mueller T, Dieplinger B, et al. B-type natriuretic peptide and amino terminal proBNP predict one-year mortality in short of breath patients independently of the baseline diagnosis of acute destabilized heart failure. Clin Chim Acta. 2006;370:174-179.
22. Januzzi JL Jr, Sakhuja R, O'Donoghue M, et al. Utility of ammo-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Arch Intern Med. 2006;166:315-320.
23. Green SM, Redmond P, Januzzi JL, et al. The impact of ammo-terminal pro-brain natriuretic peptide testing on hospital length of stay and morbidity in patients with acute decompensated heart failure. Arch Pathol Lab Med. 2007;131:473-476.
24. McCullough PA, Nowak RM, McCord J, et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation. 2002;106: 416-422.
25. Mueller C, Laule-Kilian K, Frana B, et al. The use of B-type natriuretic peptide in the management of elderly patients with acute dyspnoea. J I0ntern Med. 2005;258: 77-85.
26. Moe GW, Howlett J, Januzzi JL, et al. N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study. Circulation. 2007;115:3103-3110.
27. Januzzi JL Jr, Camargo CA, Anwaruddin S, et al. The N-terminal Pro-BNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. Am J Cardiol. 2005;95:948-954.
28. Maisel A, Hollander JE, Guss D, et al. Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. / Am Coll Cardiol. 2004;44: 1328-1333.
29. Mueller C, Laule-Kilian K, Schindler C, et al. Cost-effectiveness of B-type natriuretic peptide testing in patients with acute dyspnea. Arch Intern Med. 2006;166:1081-1087.
30. Knebel F, Schimke I, Pliet K, et al. NT-proBNP in acute heart failure: correlation with invasively measured hemodynamic parameters during recompensation. J Card Fail. 2005;ll(Suppl 5):S38-S41.
31. Di Somma S, Magrini L, Mazzone M, et al. Decrease in NTproBNP plasma levels indicates clinical improvement of acute decompensated heart failure. Am J Emerg Med. 2007;25:335-339.
32. Logeart D, Thabut G, Jourdain P, et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol. 2004;43:635-641.
33. Bettencourt P, Frioes F, Azevedo A, et al. Prognostic information provided by serial measurements of brain natriuretic peptide in heart failure. Int J Cardiol. 2004;93: 45-48.
34. Gardner RS, Chong KS, Morton JJ, et al. A change in N-terminal pro-brain natriuretic peptide is predictive of outcome in patients with advanced heart failure. Eur J Heart Fail. 2007;9:266-271.
35. Latini R, Masson S, Wong M, et al. Incremental prognostic value of changes in B-type natriuretic peptide in heart failure. Am J Med. 2006;119:70.e23-70.e30.
36. Murdoch DR, McDonagh TA, Byrne J, et al. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. Am Heart J. 1999;138(6 pt 1):1126-1132.
37. Jourdain P, Jondeau G, Funck F, et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol. 2007;49:1733-1739.
38. Shah MR, Claise KA, Bowers MT, et al. Testing new targets of therapy in advanced heart failure: the design and rationale of the Strategies for Tailoring Advanced Heart Failure Regimens in the Outpatient Setting: BRain Natriuretic Peptide Versus the Clinical CongesTion ScorE (STARBRITE) trial. Am Heart J. 2005;150:893-898.
39. Masson S, Latini R, Anand IS, et al. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clin Chem. 2006;52:1528-1538.